Global Influenza Virus Vaccine (H1N1) Market Outlook 2022

Influenza Virus Vaccine (H1N1), which is specifically designed to protect against the a (H1N1) virus, previously known as swine flu.

The global Influenza Virus Vaccine (H1N1) market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Influenza Virus Vaccine (H1N1) volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Influenza Virus Vaccine (H1N1) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Influenza Virus Vaccine (H1N1) Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.


Segment by Type
Intramuscular Vaccine
Nasal Spray Vaccine


Segment by Application
3 To 10 Years Old
10 To 18 Years Old
Above 18 Years Old
Other


By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE


By Company
CSL
NVS(Novartis)
Sanofi Pasteur
Medimmune
GSK
Baxter
Beijing Kexing Bio-Vaccine
Hualan Bio-Vaccine
Changchun Changsheng Bio-Technology
Beijing Tiantan Bio-Products
Jiangsu Yanshen Bio-Technology
Zhejiang Tianyuan Bio-Pharmaceutical
Dalian Yalifeng Bio-Pharmaceutical
Sinopharm